FDA Clears Way for Phase 1 Trial of Low-dose Oral Carbon Monoxide

The U.S. Food and Drug Administration has cleared the way for a Phase 1 trial of HBI-002, Hillhurst Biopharmaceuticals‘ oral carbon monoxide treatment for sickle cell disease (SCD).